Literature DB >> 14702186

Transcription factors involved in development and progression of malignant melanoma.

I Poser1, A-K Bosserhoff.   

Abstract

Up to date many genes are known to be deregulated in tumor development and progression. Genes important in tumorigenesis belong to families such as proteases, kinases and receptors. However, an important family of proteins is rarely discussed: the mediators of transcriptional control, the transcription factors. Usually, changes in transcription factor expression or activity can lead to more than just one downstream modification, as transcription factors are higher, thinking in a hierarchical way of expression control. In this review we summarize the role of the transcription factors AP-1, AP-2alpha, CREB, CtBP, ETS-1, HMGB1, LEF/TCF/beta-catenin, MITF, NFkappaB, PAX3, SKI, Snail and STAT in carcinogenesis focusing on melanoma development and progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14702186     DOI: 10.14670/HH-19.173

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  25 in total

1.  Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation.

Authors:  Lizi Wu; Jingxuan Liu; Ping Gao; Makoto Nakamura; Yang Cao; Huangxuan Shen; James D Griffin
Journal:  EMBO J       Date:  2005-06-16       Impact factor: 11.598

2.  Slug expression during melanoma progression.

Authors:  Stephanie H Shirley; Victoria R Greene; Lyn M Duncan; Carlos A Torres Cabala; Elizabeth A Grimm; Donna F Kusewitt
Journal:  Am J Pathol       Date:  2012-04-13       Impact factor: 4.307

Review 3.  Resistance to transforming growth factor β-mediated tumor suppression in melanoma: are multiple mechanisms in place?

Authors:  Ahmed Lasfar; Karine A Cohen-Solal
Journal:  Carcinogenesis       Date:  2010-07-23       Impact factor: 4.944

4.  Correlation of High Mobility Group Box-1 Protein (HMGB1) with Clinicopathological Parameters in Primary Retinoblastoma.

Authors:  Mithalesh Kumar Singh; Lata Singh; Neelam Pushker; Seema Sen; Anjana Sharma; Feeroj Ahamad Chauhan; Seema Kashyap
Journal:  Pathol Oncol Res       Date:  2015-06-30       Impact factor: 3.201

Review 5.  Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment.

Authors:  Russell R Braeuer; Maya Zigler; Gabriel J Villares; Andrey S Dobroff; Menashe Bar-Eli
Journal:  Semin Cancer Biol       Date:  2010-12-13       Impact factor: 15.707

6.  MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma.

Authors:  Peng Xiao; Wen-Liang Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

7.  CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma.

Authors:  Vladislava O Melnikova; Andrey S Dobroff; Maya Zigler; Gabriel J Villares; Russell R Braeuer; Hua Wang; Li Huang; Menashe Bar-Eli
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

8.  Nuclear factor-κB expression is predictive of overall survival in patients with cutaneous melanoma.

Authors:  Daniela Murtas; Franca Piras; Luigi Minerba; Jorge Ugalde; Michela Piga; Cristina Maxia; Maria Teresa Perra; Paola Sirigu
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

9.  Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.

Authors:  Kazuo Koyanagi; Steven J O'Day; Rene Gonzalez; Karl Lewis; William A Robinson; Thomas T Amatruda; Christine Kuo; He-Jing Wang; Robert Milford; Donald L Morton; Dave S B Hoon
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

10.  Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration.

Authors:  Yuchan Wang; Fang Liu; Feng Mao; Qinlei Hang; Xiaodong Huang; Song He; Yingying Wang; Chun Cheng; Huijie Wang; Guangfei Xu; Tianyi Zhang; Aiguo Shen
Journal:  J Biol Chem       Date:  2013-02-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.